In short
Lenacapavir Sodium is being studied as a potential new treatment option for people with HIV-1 who are currently on complex treatment regimens. This article explores the ongoing clinical trials that aim to evaluate the safety and effectiveness of Lenacapavir when combined with other HIV medications, particularly for patients who have limited treatment options due to viral resistance or intolerance to existing therapies.
At a glance
- Study Type
- Phase 2/3 Randomized, Open-label, Multicenter, Active-Controlled Study
- Main Objective
- Evaluate efficacy and safety of switching to Bictegravir/Lenacapavir vs. continuing current complex HIV-1 treatment
- Key Inclusion Criteria
- HIV-1 RNA < 50 copies/mL for ≥6 months, on complex ARV regimen, no resistance to bictegravir
- Key Exclusion Criteria
- Prior use of lenacapavir, active tuberculosis, chronic hepatitis B infection
- Primary Endpoints
- Proportion of participants with HIV-1 RNA ≥ 50 copies/mL at Week 24 (Phase 2) and Week 48 (Phase 3)
- Secondary Endpoints
- Viral suppression rates, CD4 cell count changes, safety and tolerability, pharmacokinetics of bictegravir and lenacapavir
- Treatment Duration
- Up to 96 weeks for some participants
What is Lenacapavir?
Lenacapavir Sodium, also known as GS-6207, is a new medication being studied for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection. It is being developed by Gilead Sciences Inc. and is currently undergoing clinical trials to evaluate its safety and effectiveness.
Medical Condition Treated
Lenacapavir is being studied for the treatment of HIV-1 infection. HIV-1 is a virus that attacks the body's immune system, making it difficult for the body to fight off infections and diseases. If left untreated, HIV-1 can lead to Acquired Immunodeficiency Syndrome (AIDS).
Study Objectives
The clinical trial for Lenacapavir has several objectives:
Main Objectives:
- To evaluate the effectiveness of switching to a bictegravir (BIC) + lenacapavir (LEN) regimen compared to continuing on a stable baseline regimen (SBR) in people with HIV-1 who have suppressed viral loads.
- To assess the efficacy of switching to a BIC/LEN fixed-dose combination (FDC) tablet regimen versus continuing on SBR.
Secondary Objectives:
- To evaluate the safety and tolerability of the treatment regimens.
- To study the pharmacokinetics (how the drug moves through the body) of BIC and LEN.
- To assess changes in CD4 cell count, which is an important measure of immune system health in HIV patients.
Eligibility Criteria
To participate in the Lenacapavir study, patients must meet certain criteria:
Inclusion Criteria:
- Have documented HIV-1 RNA levels below 50 copies/mL (indicating well-controlled HIV) for at least 6 months prior to screening.
- Be currently receiving a complex antiretroviral (ARV) regimen due to previous viral resistance, intolerance, or contraindication to existing single-tablet regimens.
- Have no documented or suspected resistance to bictegravir.
- Have an estimated glomerular filtration rate (a measure of kidney function) of ≥ 15 mL/min.
Exclusion Criteria:
- Prior use of or exposure to lenacapavir.
- Active tuberculosis infection.
- Chronic hepatitis B virus (HBV) infection.
Study Endpoints
The study will measure several outcomes to determine the effectiveness and safety of Lenacapavir:
Primary Endpoints:
- The proportion of participants with HIV-1 RNA ≥ 50 copies/mL at specific time points (24 weeks for Phase 2, 48 weeks for Phase 3).
Secondary Endpoints:
- The proportion of participants with HIV-1 RNA < 50 copies/mL at specific time points.
- Changes in CD4 cell count from baseline.
- The proportion of participants experiencing treatment-emergent adverse events (side effects).
- Pharmacokinetic parameters of BIC and LEN.
Drug Information
Lenacapavir Sodium is being studied in two forms:
- GS-6207 tablets 25 mg: A film-coated tablet containing 25 mg of Lenacapavir Sodium.
- GS-6207 tablets 50 mg: A film-coated tablet containing 50 mg of Lenacapavir Sodium.
Both forms are designed for oral use. The maximum daily dose being studied is 25 mg for the 25 mg tablet and 50 mg for the 50 mg tablet. The treatment period in the study is up to 24 weeks.
It's important to note that Lenacapavir is still being studied and is not yet approved for general use. Patients should not attempt to use or obtain this medication outside of a clinical trial setting.